Results 41 to 50 of about 1,950 (155)

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

VIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin, Galyna Bila, Ileana Manduteanu, Rostyslav Bilyy   +3 more
wiley   +1 more source

Effects of Roxadustat on the Anemia and Iron Metabolism of Patients Undergoing Peritoneal Dialysis

Frontiers in Medicine, 2021
Background: We investigated the effects of roxadustat on the anemia, iron metabolism, peritoneal membrane function, and residual renal function; and determined the factors associated with the administration of roxadustat in patients who were undergoing ...
Keiji Hirai, Hiroaki Nonaka, Moeka Ueda, Junki Morino, Shohei Kaneko, Saori Minato, Yuko Mutsuyoshi, Katsunori Yanai, Hiroki Ishii, Momoko Matsuyama, Taisuke Kitano, Akinori Aomatsu, Haruhisa Miyazawa, Kiyonori Ito, Yuichiro Ueda, Susumu Ookawara, Yoshiyuki Morishita   +16 more
doaj   +1 more source

Dendritic Cell α‐Ketoglutarate Regulates Tfh Polarization in Allergy

Allergy, EarlyView.
Allergen induces a dendritic cell metabolism shift toward glutaminolysis with α‐ketoglutarate as a regulator of Tfh subset polarization. Glutaminolysis is required for DC allergen uptake, co‐stimulatory molecule expression, and CLR expression. Modulation of glutaminolysis, JmjD3 histone demethylation, or HIF‐1α degradation alters Tfh polarization and ...
Anuj Tharakan, Xufeng Qu, Carmen Camarena, Araba Abaidoo‐Myles, Parth Naik, Jeremy Allegood, Ankit Kumar, Mihir Pokhriyal, Joseph C. Lownik, Matthew P. Zellner, Grayson W. Way, Jinze Liu, Lauren Ashley Cowart, Stephanie C. Eisenbarth, Joseph W. Landry, Daniel H. Conrad, Rebecca K. Martin   +16 more
wiley   +1 more source

The Efficacy and Safety of Roxadustat for Anemia in Hemodialysis Patients with Chronic Kidney Disease: A Meta-Analysis of Randomized Controlled Trials

Toxics
Background: Patients undergoing hemodialysis (HD) for chronic kidney disease (CKD) often encounter anemia. Roxadustat has not only undergone phase II-III clinical trials in patients suffering from CKD and undergoing HD; a number of post-marketing ...
Yunling Geng, Shuaixing Zhang, Zijing Cao, Jingyi Tang, Hailan Cui, Zhaocheng Dong, Yuning Liu, Weijing Liu   +7 more
doaj   +1 more source

Effect of roxadustat and erythropoiesis-stimulating agents on efficacy in peritoneal dialysis patients

徐州医科大学学报
Objective To compare the effects of roxadustat versus erythropoiesis-stimulating agents (ESAs) on anemia and cardiovascular safety in peritoneal dialysis (PD) patients.Methods A retrospective analysis was conducted on 205 PD patients who were admitted to
HUANG Ruihua, LIU Jie, ZHOU Xinglei, MENG Chen, LIU Kun, LI Shuang, SUN Dong   +6 more
doaj   +1 more source

Effect of roxadustat on iron metabolism in patients with peritoneal dialysis: a real-world 24-week study

European Journal of Medical Research, 2023
Background Roxadustat is an oral hypoxia inducing factor-prolyl hydroxylase inhibitor (HIF-PHI) that regulates iron metabolism in patients with chronic kidney disease (CKD) primarily by reducing hepcidin levels and mobilizing internal iron stores.
Xuejie Zhang, Ruoyu Jia, Zhifang Zheng, Luhua Jiang, Yizhou Xu, Ashok Raj, Dong Sun   +6 more
doaj   +1 more source

Hypercapnia Induces Mitochondrial Adaptations and Alters Glutamine Metabolism to Drive a Distinct Metabolic Phenotype in Monocytes

Immunology &Cell Biology, EarlyView.
Elevated CO2 (hypercapnia) is a feature of serious lung diseases, for example COPD and contributes to poor patient prognosis through modulation of immune cell function. Here we employ state‐of‐the art metabolomic and isotope tracing approaches to reveal CO2‐dependent mitochondrial alterations linked to suppressed ATP, proline and glutamate levels in ...
Ben Reddan, David E. Phelan, Xiaofei Yin, Lorraine Brennan, Martina Wallace, Eoin P. Cummins   +5 more
wiley   +1 more source

Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis : a European phase 3, randomized, open-label, active-controlled study (PYRENEES) [PDF]

, 2021
Introduction: Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor being developed for the treatment of anemia of chronic kidney disease (CKD).
Csiky, Botond, Reusch, Michael, Barratt, Jonathan, Valluri, Udaya, Schomig, Michael, Esposito, Ciro, Sułowicz, Władysław   +6 more
core   +1 more source

Roxadustat regulates iron metabolism in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A meta-analysis

Journal of the Formosan Medical Association, 2022
Background/Purpose: The effect of roxadustat on iron homeostasis in patients with chronic kidney disease (CKD) is unclear. This study aimed to evaluate the efficacy of roxadustat for the treatment of iron metabolism disorders in dialysis-dependent (DD ...
Yan-Pei Hou, Chang Wang, Xin-Yue Mao, Man-Zhu Zhang, Bing Li   +4 more
doaj   +1 more source

TNFSF14/LIGHT responses in intestinal and oesophageal fibroblasts are differentially modulated by hydroxylase inhibitors

The Journal of Physiology, EarlyView.
Abstract figure legend LIGHT is a mutual mediator of intestinal and oesophageal fibroblast inflammation with common as well as tissue‐specific effects. Hydroxylase inhibitors can selectively suppress inflammatory factors in both cell types, albeit targeting different signalling pathways.
Cian M. Ohlendieck, Carlos Matellan, Cristina Bauset, Bella Raphael, Mary Nwaezeigwe, Emer Flynn, Kevin Okamoto, Desmond Winter, Colm Collins, Katie Doogan, Seán T. Martin, Glen Doherty, Seema S. Aceves, Mario C. Manresa   +13 more
wiley   +1 more source